International Clinical Trial: A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816380) titled 'A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Guangzhou JOYO Pharma Co., Ltd

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)

Intervention: Drug: JYP0322 Tablets

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 30, 2026

Target Sample Size: 216 ...